AngioDynamics, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and first six months ended November 30, 2023. Figures are unaudited. Dollar amounts are in millions unless stated otherwise.
Business context and key financial metrics
AngioDynamics develops and sells medical devices for vascular access, peripheral vascular disease, oncology and surgical uses. It reports two segments: Med Tech and Med Device. On June 8, 2023, the company sold its dialysis and BioSentry businesses to Merit Medical for $100.0 million in cash; the sale was not classified as discontinued operations.
| Metric | Three months ended Nov. 30, 2023 | Six months ended Nov. 30, 2023 |
|---|---|---|
| Net sales | $79.1; down 7.4% year over year | $157.8; down 5.5% |
| Gross profit / margin | $40.3 / 50.9%; prior-year margin 52.8% | $80.3 / 50.9%; prior-year margin 52.3% |
| Operating income (loss) | ($13.1) | $21.9 |
| Net income (loss) | ($29.0); diluted loss per share $0.72 | $16.8; diluted earnings per share $0.42 |
| Operating cash flow | Not separately presented for the quarter | Cash used of $20.6, versus $17.2 used a year earlier |
Six-month net income includes a $47.8 million pretax gain on the divestiture. The second-quarter tax expense was $16.4 million despite a pretax loss of $12.6 million, contributing to the net loss; the filing attributes tax-rate differences primarily to valuation allowances, foreign taxes and nondeductible items. The six-month effective tax rate, including discrete items, was 24.3%.
At November 30, cash and cash equivalents were $60.9 million, compared with $44.6 million at May 31. The company had no debt, following repayment of $50.0 million upon the divestiture. Current assets were $185.5 million and current liabilities were $78.0 million. Cash increased by $16.3 million during the six months, reflecting $100.0 million of divestiture proceeds, partly offset by debt repayment and other financing outflows.
Changes versus prior comparable periods
- Revenue fell by $6.4 million in the quarter and $9.2 million in the six-month period. Management said the divested businesses reduced comparable sales by $8.4 million and $16.2 million, respectively.
- Med Tech sales rose 3.5% in the quarter and 8.3% over six months; Med Device sales declined 11.8% and 11.0%, respectively. Med Tech growth included Auryon and NanoKnife, partly offset by softness in thrombus management.
- Med Tech gross margin was 62.4% for the quarter and 63.5% for six months. Med Device margins were 45.5% and 44.9%, respectively. Company-wide margin declines reflected the divestiture, sales mix and inflationary costs, among other factors.
- Quarterly net loss widened from $8.5 million to $29.0 million. Six-month results moved from a $21.5 million loss to $16.8 million of income, primarily reflecting the divestiture gain.
- Research and development expense rose to $8.7 million for the quarter, mainly due to timing of projects and clinical-trial spending. Acquisition, restructuring and other items totaled $6.2 million for the quarter, including $5.3 million of litigation expense.
Outlook, risks and unusual items
- Management said existing cash and anticipated operating cash flows should be sufficient for expected capital needs for at least 12 months. The filing provides no quantified revenue or earnings guidance.
- On January 5, 2024, the company announced a plan to shift manufacturing from company-owned upstate New York facilities to a fully outsourced model, targeting lower structural and overhead costs. The restructuring is expected to be completed in fiscal Q3 2026.
- Management cited ongoing risks from manufacturing and supply-chain reliability, labor shortages, inflation and raw-material availability, competition, regulation, clinical results, product liability and litigation, foreign exchange, and execution of strategic initiatives.
- Several Bard patent disputes remain pending. A jury trial in one case is scheduled for April 29, 2024; Bard appealed a June 2023 judgment in the company’s favor in another case. The company recorded no litigation expense for potential losses in these matters because loss was not considered both probable and reasonably estimable.
- Contingent consideration was $9.4 million at November 30, with approximately $10.0 million of undiscounted future payments expected across completed acquisitions. The company also maintains valuation allowances on certain deferred tax assets, subject to reassessment.
Important facts for investors to verify
- How much of future sales and margin performance reflects the divestiture versus underlying demand, especially in Med Device and Med Tech?
- Whether manufacturing outsourcing delivers expected savings, and what transition, restructuring or execution costs arise before completion.
- Whether operating cash use improves as inventory and prepaid expenses are managed; six-month operating cash flow was negative despite reported net income.
- Developments and potential financial exposure in the Bard litigation and the timing and amount of acquisition earn-out payments.
- Whether sustained profitability provides sufficient evidence to change deferred-tax valuation allowances, and how future tax expense compares with pretax results.